N-[[(2S)-1-Ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-3-iodo-6-methoxybenzamide
-
![N-[[(2S)-1-Ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-3-iodo-6-methoxybenzamide structure](https://file.echemi.com/fileManage/upload/canonicalSmiles/20220811/65baa61be0ed4a32a2ca011d3f575181.png "N-[[(2S)-1-Ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-3-iodo-6-methoxybenzamide")
N-[[(2S)-1-Ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-3-iodo-6-methoxybenzamide
structure -
-
CAS No:
84226-06-2
-
Formula:
C15H21IN2O3
-
Chemical Name:
N-[[(2S)-1-Ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-3-iodo-6-methoxybenzamide
-
Synonyms:
Benzamide,N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-3-iodo-6-methoxy-;Benzamide,N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-hydroxy-3-iodo-6-methoxy-,(S)-;N-[[(2S)-1-Ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-3-iodo-6-methoxybenzamide;IBZM;(S)-(-)-IBZM;(S)-(-)-3-Iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide
-
CAS No:
N-[[(2S)-1-Ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-3-iodo-6-methoxybenzamide Basic Attributes
404.24
404.24
9J5D4ZN1JK
Characteristics
61.8
2.54830
dark yellow oil
1.51 g/cm3
426.9ºC at 760 mmHg
212ºC
H2O: <0.5 mg/mL, slightly soluble
2-8°C
Drug Information
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)|Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)
123I-IBZM
N-[[(2S)-1-Ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-3-iodo-6-methoxybenzamide Use and Manufacturing
A halogenated benzamide derivative as potential radioligands for non-invasive quantification of D2-like dopamine receptor. The main purpose of a brain study with IBZM is the differentiation of Parkinson’s disease from other neurodegenerative diseases like Lewy Body dementia, multiple system atrophy.
Computed Properties
Molecular Weight:404.24
XLogP3:2.3
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:4
Rotatable Bond Count:5
Exact Mass:404.05969
Monoisotopic Mass:404.05969
Topological Polar Surface Area:61.8
Heavy Atom Count:21
Complexity:356
Defined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
N-[[(2S)-1-Ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-3-iodo-6-methoxybenzamide
SDSRequest for Quotation